95 related articles for article (PubMed ID: 23043453)
1. Treatment of HIV infection with once-daily regimens.
Permpalung N; Putcharoen O; Avihingsanon A; Ruxrungtham K
Expert Opin Pharmacother; 2012 Nov; 13(16):2301-17. PubMed ID: 23043453
[TBL] [Abstract][Full Text] [Related]
2. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment.
Olin JL; Spooner LM; Klibanov OM
Ann Pharmacother; 2012 Dec; 46(12):1671-7. PubMed ID: 23136357
[TBL] [Abstract][Full Text] [Related]
3. Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment.
Llibre JM; Clotet B
AIDS Rev; 2012; 14(3):168-78. PubMed ID: 22833060
[TBL] [Abstract][Full Text] [Related]
4. Comparative safety review of recommended, first-line single-tablet regimens in patients with HIV.
Ciccullo A; Baldin G; Putaggio C; Di Giambenedetto S; Borghetti A
Expert Opin Drug Saf; 2021 Nov; 20(11):1317-1332. PubMed ID: 34018892
[No Abstract] [Full Text] [Related]
5. Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection.
Bollen P; Reiss P; Schapiro J; Burger D
Expert Opin Drug Saf; 2015; 14(9):1457-72. PubMed ID: 26134478
[TBL] [Abstract][Full Text] [Related]
6. Once-daily nevirapine XR: a brief overview of the safety and efficacy of a new formulation.
Bhatti L; Gladstein J
J Int Assoc Physicians AIDS Care (Chic); 2012; 11(6):369-73. PubMed ID: 22930796
[TBL] [Abstract][Full Text] [Related]
7. Cobicistat: a new boost for the treatment of human immunodeficiency virus infection.
Shah BM; Schafer JJ; Priano J; Squires KE
Pharmacotherapy; 2013 Oct; 33(10):1107-16. PubMed ID: 23471741
[TBL] [Abstract][Full Text] [Related]
8. Initiation of antiretroviral therapy: implications of recent findings.
Saag MS
Top HIV Med; 2004; 12(3):83-8. PubMed ID: 15310939
[TBL] [Abstract][Full Text] [Related]
9. Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients.
Maggiolo F; Ripamonti D; Gregis G; Quinzan G; Callegaro A; Arici C; Ravasio L; Suter F
Antivir Ther; 2003 Aug; 8(4):339-46. PubMed ID: 14518703
[TBL] [Abstract][Full Text] [Related]
10. Adherence and persistence with non-nucleoside reverse transcriptase inhibitor-based antiretroviral regimens.
Taneja C; Juday T; Gertzog L; Edelsberg J; Correll T; Hebden T; Oster G
Expert Opin Pharmacother; 2012 Oct; 13(15):2111-8. PubMed ID: 22970926
[TBL] [Abstract][Full Text] [Related]
11. Persistence and adherence to single-tablet regimens in HIV treatment: a cohort study from the French National Healthcare Insurance Database.
Raffi F; Yazdanpanah Y; Fagnani F; Laurendeau C; Lafuma A; Gourmelen J
J Antimicrob Chemother; 2015 Jul; 70(7):2121-8. PubMed ID: 25904729
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US.
Juday T; Correll T; Anene A; Broder MS; Ortendahl J; Bentley T
Clinicoecon Outcomes Res; 2013; 5():437-45. PubMed ID: 24039438
[TBL] [Abstract][Full Text] [Related]
13. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
14. [Two novel fixed formulations of nucleoside analogues (tenofovir-emtricitabine, and abacavir-lamivudine). Prospective, open study on clinical practice and therapeutic perspectives, in patients naïve and in subjects pre-treated with antiretrovirals].
Manfredi R; Calza L
Recenti Prog Med; 2008 Oct; 99(10):492-501. PubMed ID: 19040127
[TBL] [Abstract][Full Text] [Related]
15. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic perspectives for once-daily antiretroviral therapy.
Anderson PL
Ann Pharmacother; 2004 Nov; 38(11):1924-34. PubMed ID: 15479772
[TBL] [Abstract][Full Text] [Related]
17. Anti-HIV drugs.
De Clercq E
Verh K Acad Geneeskd Belg; 2007; 69(2):81-104. PubMed ID: 17550060
[TBL] [Abstract][Full Text] [Related]
18. [Initial antiretroviral therapy in HIV-infected patients].
Cormier H; Hoen B
Rev Prat; 2014 Oct; 64(8):1079-85. PubMed ID: 25510130
[TBL] [Abstract][Full Text] [Related]
19. Single-Tablet Regimens in HIV Therapy.
Astuti N; Maggiolo F
Infect Dis Ther; 2014 Jun; 3(1):1-17. PubMed ID: 25134808
[TBL] [Abstract][Full Text] [Related]
20. Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial.
Miró JM; Manzardo C; Pich J; Domingo P; Ferrer E; Arribas JR; Ribera E; Arrizabalaga J; Loncá M; Cruceta A; de Lazzari E; Fuster M; Podzamczer D; Plana M; Gatell JM;
AIDS Res Hum Retroviruses; 2010 Jul; 26(7):747-57. PubMed ID: 20624069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
